Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SDHB | P21912 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611938 | 0.92 | LTA4H (0.40) | CYP3A4CYP2C19ALOX5APFEN1LTA4H | |
| SCHEMBL21614743 | 0.83 | DAO (0.38) | LOXLOXL2MEN1NPC1RAB9A | |
| SCHEMBL21614744 | 0.81 | HDAC1 (0.36) | CYP3A4CYP2C19ALOX5APFEN1CHRM5 | |
| SCHEMBL21614746 | 0.81 | LOXL2 (0.35) | CYP2C19ALOX5APFEN1LOXLOXL2 | |
| SCHEMBL21612047 | 0.80 | PPARD (0.48) | CYP3A4CYP2C19ALOX5APFEN1PDE10A | |
| SCHEMBL21614660 | 0.78 | CYP2C19 (0.63) | CYP3A4CYP2C19ALOX5APFEN1CHRM5 | |
| SCHEMBL21614668 | 0.77 | CYP3A4 (0.67) | CYP3A4CYP2C19 | |
| SCHEMBL21611924 | 0.76 | CDK2 (0.38) | CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL21611945 | 0.75 | LOXL2 (0.38) | LOXLOXL2MEN1KMT2A | |
| SCHEMBL15454013 | 0.73 | LOXL2 (0.46) | CYP3A4SCN9ALOXLOXL2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-01-30 | — | — | US | disclosed |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3818045-A1 | PQSR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | QRFPR, P2RY11, QARS1 | CYP3A4 3080/4885CYP2C19 1824/4885ALOX5AP 1117/4885 |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | QRFPR, P2RY11, QARS1 | CYP3A4 3080/4885CYP2C19 1824/4885ALOX5AP 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.